Jiayu Biotech completes tens of millions of dollars in Series B financing

Recently, Jiayu Biopharmaceutical Co., Ltd. (Jiayu Bio) announced the completion of its Series B financing. This round of financing was led by VMS Group, a Hong Kong investment institution, and followed by Panacea Venture. This round of financing will be used for the purchase of instruments and equipment, reagent consumables, personnel recruitment and company operations, and the purchase of technical patents for the new biopharmaceutical GMP testing business.

Founded in June 2017, Jiayu Bio is the first company to propose a new business model of Bio-CQO®, biopharmaceutical quality contracting service and has a registered trademark. In the past 5 years, in terms of GMP quality system, product QA/QC/QV and related drug regulatory registration and application services, Jade Bio has successfully helped customers deliver IND to BLA applications for more than 50 projects, including biomacromolecules in China and the United States. Leading industrialization companies, including monoclonal antibody, ADC, CAR-T and other CGT, mRNA product companies and leading CDMOs in China and the United States.